AUVELIA TABLET 10'S

Content Reviewed By:

Written By:

• A Novel Approach to Managing Hyperphosphatemia: AUVELIA (Ferric Citrate) offers a groundbreaking method for controlling elevated phosphate levels in the blood, a common and serious concern for individuals with chronic kidney disease (CKD) undergoing dialysis. Unlike traditional phosphate binders, AUVELIA not only effectively lowers phosphate levels but also provides a source of iron, addressing iron deficiency, another frequent complication in CKD patients. This dual-action mechanism simplifies treatment regimens and potentially reduces the pill burden for patients.
• Effective Phosphate Control: The primary benefit of AUVELIA lies in its ability to significantly reduce serum phosphate levels. By binding to dietary phosphate in the gastrointestinal tract, AUVELIA prevents its absorption into the bloodstream, thus helping to maintain phosphate levels within the target range recommended by healthcare professionals. This is crucial in preventing or mitigating the long-term consequences of hyperphosphatemia, such as cardiovascular disease, bone disorders, and soft tissue calcification.
• Iron Supplementation: AUVELIA distinguishes itself by simultaneously providing iron supplementation. The ferric citrate component delivers iron, which is absorbed into the bloodstream and contributes to improving iron stores and managing anemia, a prevalent issue among dialysis patients. This eliminates the need for separate iron supplements in some cases, streamlining medication management and potentially improving patient adherence.
• Improved Patient Adherence: The dual-action benefit of phosphate control and iron supplementation can lead to better patient compliance. By combining two essential treatments into a single medication, AUVELIA simplifies the treatment regimen, making it easier for patients to adhere to their prescribed therapy. This, in turn, can lead to more effective management of hyperphosphatemia and iron deficiency.
• Cardiovascular Health Benefits: Maintaining optimal phosphate levels with AUVELIA can contribute to improved cardiovascular health in CKD patients. Hyperphosphatemia is a known risk factor for cardiovascular disease, and effective phosphate control can reduce the risk of arterial calcification, heart attacks, and strokes. By addressing both phosphate imbalance and iron deficiency, AUVELIA supports overall cardiovascular well-being.
• Bone Health Support: Elevated phosphate levels can disrupt bone metabolism and lead to renal osteodystrophy, a condition characterized by weakened bones and increased fracture risk. AUVELIA helps to maintain phosphate balance, which is essential for healthy bone turnover and mineralization. This can help to prevent or slow the progression of renal osteodystrophy and improve bone health in CKD patients.
• Reduced Pill Burden: Many CKD patients on dialysis require multiple medications to manage various complications. AUVELIA's dual-action mechanism can reduce the overall number of pills that patients need to take, improving convenience and adherence. This can significantly improve the patient's quality of life and make it easier to manage their health.
• Well-Tolerated Profile: Clinical trials have demonstrated that AUVELIA is generally well-tolerated, with a favorable safety profile. While some patients may experience gastrointestinal side effects such as diarrhea or constipation, these are typically mild to moderate in severity. The overall tolerability of AUVELIA contributes to its effectiveness in long-term management of hyperphosphatemia and iron deficiency.
• Improved Quality of Life: By effectively managing hyperphosphatemia and iron deficiency, AUVELIA can significantly improve the quality of life for CKD patients on dialysis. Improved energy levels, reduced fatigue, better cardiovascular health, and stronger bones can all contribute to a greater sense of well-being and the ability to participate more fully in daily activities.

• AUVELIA TABLET 10'S is a medication primarily used to control serum phosphorus levels in adults with chronic kidney disease (CKD) who are on dialysis. It is vital to take this medication exactly as prescribed by your healthcare provider. Do not alter the dosage or frequency without consulting them first.
• Typically, AUVELIA is taken with meals. The usual starting dose is determined by your doctor based on your phosphorus levels. Swallow the tablets whole; do not crush, chew, or break them. If you have difficulty swallowing, discuss alternative options with your doctor or pharmacist.
• Consistency is key to the effectiveness of AUVELIA. Try to take it at the same time each day with your meals to maintain a steady level of medication in your system. If you miss a dose, take it as soon as you remember, provided it's still during or shortly after a meal. If it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not double your dose to make up for a missed one.
• During treatment with AUVELIA, your doctor will regularly monitor your phosphorus levels to assess how well the medication is working and adjust your dosage as needed. It is crucial to attend all scheduled appointments and undergo the necessary blood tests. Inform your doctor about all other medications, supplements, and over-the-counter products you are taking, as they may interact with AUVELIA. Potential side effects should also be promptly reported to your healthcare provider.
• Store AUVELIA tablets as directed by the packaging or your pharmacist, typically in a cool, dry place away from direct sunlight and moisture. Keep out of reach of children. Properly dispose of any unused medication according to local regulations. If you have any questions or concerns about using AUVELIA, consult your doctor or pharmacist for personalized guidance.